Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05228132 · ClinicalTrials.gov registry record · NA
The Pristine Post-Market Study
A NA study, sponsored by C. R. Bard.
- Terminated
- Registry status
- NA
- Development phase
- 142
- Enrollment target
NCT05228132: Clinical Trial NA study, sponsored by C. R. Bard.
NCT05228132 is a NA study that was terminated before completion, run by C. R. Bard. The registered enrollment target is 142 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05228132, a NA study, was terminated before completion, sponsored by C. R. Bard.
- TERMINATED
- Registry status
- NA
- Development phase
- 142 participants
- Enrollment target
Study Summary
This is a prospective, multi-center, single-arm study designed to assess the safety and performance of the Pristine™ Long-Term Hemodialysis Catheter.
Primary Outcome
The combined Primary Endpoint is the overall rate of infectious complications and non-infectious complications requiring revision to maintain patency and improve access performance, evaluated against a performance goal (PG) derived from the Dialysis Outcomes and Practice Patterns Study (DOPPS) data.
Interventions
- DEVICE Pristine™ Long-Term Hemodialysis Catheter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2022-05-16 |
| Est. Completion | 2022-09-21 |
| Phase | NA |
Why NCT05228132 stopped before completion
NCT05228132 is an interventional study that assigns participants to a tested intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which Pristine™ Long-Term Hemodialysis Catheter is the first listed.
NCT05228132 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05228132 about?
NCT05228132 is a clinical study titled "The Pristine Post-Market Study". This is a prospective, multi-center, single-arm study designed to assess the safety and performance of the Pristine™ Long-Term Hemodialysis Catheter.
What is the current status of trial NCT05228132?
This trial is currently terminated. It is a NA study. The enrollment target is 142 participants. The study started on 2022-05-16. Estimated completion is 2022-09-21.
What interventions are being tested in trial NCT05228132?
The interventions under investigation include: Pristine™ Long-Term Hemodialysis Catheter (DEVICE).
Who is sponsoring clinical trial NCT05228132?
This trial is sponsored by C. R. Bard, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05228132's enrollment target sits among peer trials
142 711th of 2000 higher than 1,289 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI